• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Oral P2Y12 inhibitor pretreatment offers no benefit in non-ST elevation acute coronary syndromes

byJake EngelandMichael Pratte
May 13, 2022
in Cardiology, Chronic Disease, Emergency
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Pretreatment with oral P2Y12 inhibitors in patients with non-ST elevation acute coronary syndromes demonstrated no reduction in major cardiovascular events, yet an increase in bleeding risk, at 30 days compared to patients who did not receive pretreatment.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Oral P2Y12 inhibitors are commonly used in patients with non-ST elevation acute coronary syndromes (NSTEACS) while awaiting percutaneous coronary intervention (PCI). However, it is unclear whether pretreatment (administration of medication prior to angiography) with PGY12 inhibitors improves cardiovascular outcomes. This systematic review and meta-analysis investigated the association of oral P2Y12 inhibitor pretreatment with cardiovascular and bleeding outcomes in patients with NSTEACS. Studies published before March 20, 2021, were included if: they were a randomized clinical trial (RCT), enrolled patients with NSTEACS, and compared pretreatment versus no pretreatment with oral P2Y12 inhibitors. The primary outcomes were major adverse cardiovascular events (MACEs) and major bleeding events at 30 days where possible. There were seven RCTs included with 13 226 patients. At the primary endpoint, there were no differences in MACEs between patients who received oral P2Y12 inhibitor pretreatment and those that did not (odds ratio [OR]: 0.95 [95% CI: 0.78-1.15]; I2 = 28%). The lack of significant difference was also observed for 30-day myocardial infarction risk and 30-day cardiovascular death risk. Furthermore, major bleeding risk at 30 days was higher among those who received P2Y12 inhibitor pretreatment compared to patients who did not (OR: 1.51 [95% CI: 1.16-1.97]; I2 = 41%). On average, one major bleeding event with pretreatment occurred in every 63 patients. Notably, there was an exception in patients who received clopidogrel (a type of oral P2Y12 inhibitor). Pretreatment with clopidogrel decreased the risk of MACEs compared to no pretreatment (OR: 0.77 [95% CI: 0.62-0.97]). Overall, despite the widespread use of P2Y12 inhibitors as pretreatment for patients with NSTEACS, their application is not supported by this systematic review and may instead be harmful as bleeding risk increases with its use. One limitation of this study, however, is that there were different time intervals from pretreatment to angiography in these studies, which may have played a factor in the outcomes of these studies.

Click to read the study in JAMA Network Open

Click to read an accompanying editorial in JAMA

Relevant Reading: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Image: PD

RELATED REPORTS

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy

Contemporary pattern of treatment time and in-hospital mortality among US patients with ST-segment elevation myocardial infarction between 2018-2021

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: clopclopidogrelnstemiP2Y12 inhibitorSTEMI
Previous Post

#VisualAbstract: Physical activity interventions may improve symptoms of attention-deficit/hyperactivity disorder  

Next Post

#VisualAbstract: Adequate antibody response to mRNA-1273 COVID-19 vaccine occurs in patients with cancer

RelatedReports

Cardiology

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

December 26, 2022
Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease
Cardiology

Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy

December 6, 2022
Propofol appears safe and effective in procedural sedation for cardioversion
Cardiology

Contemporary pattern of treatment time and in-hospital mortality among US patients with ST-segment elevation myocardial infarction between 2018-2021

November 9, 2022
Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED
Cardiology

Complete revascularization vs. lesion only percutaneous coronary intervention for STEMI

September 30, 2022
Next Post
#VisualAbstract: Adequate antibody response to mRNA-1273 COVID-19 vaccine occurs in patients with cancer

#VisualAbstract: Adequate antibody response to mRNA-1273 COVID-19 vaccine occurs in patients with cancer

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial

Wellness Check: Addictions

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Dual therapy with infliximab and IVIG in children with multi-system inflammatory syndrome

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options